Literature DB >> 30136572

Delivering Hematopoietic Stem Cell Gene Therapy Treatments for Neurological Lysosomal Diseases.

Rebecca J Holley1, Shaun R Wood1, Brian W Bigger1.   

Abstract

Neurological lysosomal storage diseases are rare, inherited conditions resulting mainly from lysosomal enzyme deficiencies. Current treatments, such as enzyme replacement therapy and hematopoietic stem cell transplantation, fail to effectively treat neurological disease due to insufficient brain delivery of the missing enzyme. Ex vivo gene therapy approaches to overexpress the missing enzyme in hematopoietic stem cells prior to transplant are an emerging technology that has the potential to offer a viable therapy for patients with these debilitating diseases.

Entities:  

Keywords:  enzyme replacement therapy; gene therapy; hematopoietic stem cells; lysosomal storage diseases; mucopolysaccharidoses

Mesh:

Year:  2018        PMID: 30136572     DOI: 10.1021/acschemneuro.8b00408

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  3 in total

1.  Intravenous infusion of iPSC-derived neural precursor cells increases acid β-glucosidase function in the brain and lessens the neuronopathic phenotype in a mouse model of Gaucher disease.

Authors:  Yanyan Peng; Benjamin Liou; Venette Inskeep; Rachel Blackwood; Christopher N Mayhew; Gregory A Grabowski; Ying Sun
Journal:  Hum Mol Genet       Date:  2019-10-15       Impact factor: 6.150

Review 2.  Stem Cell Research Tools in Human Metabolic Disorders: An Overview.

Authors:  Serena Ricci; Pietro Cacialli
Journal:  Cells       Date:  2021-10-07       Impact factor: 6.600

Review 3.  Delivering gene therapy for mucopolysaccharide diseases.

Authors:  Shaun R Wood; Brian W Bigger
Journal:  Front Mol Biosci       Date:  2022-09-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.